Literature DB >> 26206800

Tandem autologous-allogeneic stem cell transplantation as a feasible and effective procedure in high-risk lymphoma patients.

Roberto Crocchiolo1, Luca Castagna2, Sylvain Garciaz3, Sabine Fürst3, Jean El Cheikh3, Barbara Sarina2, Stefania Bramanti2, Angela Granata3, Andrea Vai2, Samia Harbi3, Lucio Morabito2, Bilal Mohty3, Laura Giordano4, Raynier Devillier3, Diane Coso3, Monica Balzarotti2, Christian Chabannon3, Carmelo Carlo-Stella2, Armando Santoro2, Reda Bouabdallah3, Didier Blaise3.   

Abstract

Entities:  

Keywords:  efficacy; high-risk; lymphoma; tandem stem cell transplantation

Mesh：

Year:  2015        PMID： 26206800      PMCID： PMC4591781          DOI： 10.3324/haematol.2015.129452

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  15 in total

1.  Tandem autologous-allogeneic nonmyeloablative sibling transplantation in relapsed follicular lymphoma leads to impressive progression-free survival with minimal toxicity.

Authors:  Sandra Cohen; Thomas Kiss; Silvy Lachance; Denis Claude Roy; Guy Sauvageau; Lambert Busque; Imran Ahmad; Jean Roy
Journal:  Biol Blood Marrow Transplant       Date:  2011-12-07       Impact factor: 5.742

2.  Tandem autologous-allo-SCT is feasible in patients with high-risk relapsed non-Hodgkin's lymphoma.

Authors:  R Crocchiolo; L Castagna; S Fürst; J El-Cheikh; C Faucher; C Oudin; A Granata; R Bouabdallah; D Coso; C Chabannon; M Balzarotti; A Santoro; D Blaise
Journal:  Bone Marrow Transplant       Date:  2012-06-25       Impact factor: 5.483

3.  A response-adjusted PET-based transplantation strategy in primary resistant and relapsed Hodgkin Lymphoma.

Authors:  K J Thomson; I Kayani; K Ardeshna; E C Morris; R Hough; A Virchis; A H Goldstone; D C Linch; K S Peggs
Journal:  Leukemia       Date:  2012-11-08       Impact factor: 11.528

4.  Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma.

Authors:  T Philip; C Guglielmi; A Hagenbeek; R Somers; H Van der Lelie; D Bron; P Sonneveld; C Gisselbrecht; J Y Cahn; J L Harousseau
Journal:  N Engl J Med       Date:  1995-12-07       Impact factor: 91.245

5.  Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era.

Authors:  Christian Gisselbrecht; Bertram Glass; Nicolas Mounier; Devinder Singh Gill; David C Linch; Marek Trneny; Andre Bosly; Nicolas Ketterer; Ofer Shpilberg; Hans Hagberg; David Ma; Josette Brière; Craig H Moskowitz; Norbert Schmitz
Journal:  J Clin Oncol       Date:  2010-07-26       Impact factor: 44.544

6.  Analysis of prognostic factors after the first relapse of Hodgkin's disease in 187 patients.

Authors:  P Brice; Y Bastion; M Divine; G Nedellec; A Ferrant; J Gabarre; O Reman; E Lepage; C Fermé
Journal:  Cancer       Date:  1996-09-15       Impact factor: 6.860

7.  Reduced-intensity conditioning for allogeneic haematopoietic stem cell transplantation in relapsed and refractory Hodgkin lymphoma: impact of alemtuzumab and donor lymphocyte infusions on long-term outcomes.

Authors:  Karl S Peggs; Anna Sureda; Wendi Qian; Dolores Caballero; Ann Hunter; Alvaro Urbano-Ispizua; James Cavet; Josep M Ribera; Anne Parker; Miguel Canales; Premini Mahendra; Javier Garcia-Conde; Donald Milligan; Guillermo Sanz; Kirsty Thomson; Reyes Arranz; Anthony H Goldstone; Ivan Alvarez; David C Linch; Jorge Sierra; Stephen Mackinnon
Journal:  Br J Haematol       Date:  2007-10       Impact factor: 6.998

8.  Defining the intensity of conditioning regimens: working definitions.

Authors:  Andrea Bacigalupo; Karen Ballen; Doug Rizzo; Sergio Giralt; Hillard Lazarus; Vincent Ho; Jane Apperley; Shimon Slavin; Marcelo Pasquini; Brenda M Sandmaier; John Barrett; Didier Blaise; Robert Lowski; Mary Horowitz
Journal:  Biol Blood Marrow Transplant       Date:  2009-09-01       Impact factor: 5.742

9.  Early failure of frontline rituximab-containing chemo-immunotherapy in diffuse large B cell lymphoma does not predict futility of autologous hematopoietic cell transplantation.

Authors:  Mehdi Hamadani; Parameswaran N Hari; Ying Zhang; Jeanette Carreras; Görgün Akpek; Mahmoud D Aljurf; Ernesto Ayala; Veronika Bachanova; Andy I Chen; Yi-Bin Chen; Luciano J Costa; Timothy S Fenske; César O Freytes; Siddhartha Ganguly; Mark S Hertzberg; Leona A Holmberg; David J Inwards; Rammurti T Kamble; Edward J Kanfer; Hillard M Lazarus; David I Marks; Taiga Nishihori; Richard Olsson; Nishitha M Reddy; David A Rizzieri; Bipin N Savani; Melhem Solh; Julie M Vose; Baldeep Wirk; David G Maloney; Sonali M Smith; Silvia Montoto; Wael Saber; Onder Alpdogan; Amanda Cashen; Christopher Dandoy; Robert Finke; Robert Gale; John Gibson; Jack W Hsu; Nalini Janakiraman; Mary J Laughlin; Michael Lill; Mitchell S Cairo; Reinhold Munker; Phil A Rowlings; Harry C Schouten; Thomas C Shea; Patrick J Stiff; Edmund K Waller
Journal:  Biol Blood Marrow Transplant       Date:  2014-07-05       Impact factor: 5.742

10.  Rituximab after lymphoma-directed conditioning and allogeneic stem-cell transplantation for relapsed and refractory aggressive non-Hodgkin lymphoma (DSHNHL R3): an open-label, randomised, phase 2 trial.

Authors:  Bertram Glass; Justin Hasenkamp; Gerald Wulf; Peter Dreger; Michael Pfreundschuh; Martin Gramatzki; Gerda Silling; Christian Wilhelm; Matthias Zeis; Anke Görlitz; Sebastian Pfeiffer; Reinhard Hilgers; Lorenz Truemper; Norbert Schmitz
Journal:  Lancet Oncol       Date:  2014-05-11       Impact factor: 41.316
View more
  3 in total

1.  Outcomes of Hodgkin lymphoma patients who relapse after allogeneic stem cell transplantation.

Authors:  L Castagna; B Sarina; R Crocchiolo; S Bramanti; S Furst; R Devillier; D Coso; R Bouabdallah; D Mokart; L Morabito; S Harbi; L Giordano; A Rimondo; P Jean Weiller; C Carlo-Stella; A Santoro; C Chabannon; D Blaise
Journal:  Bone Marrow Transplant       Date:  2016-10-17       Impact factor: 5.483

2.  High-dose etoposide could discriminate the benefit from autologous peripheral blood stem cell transplantation in the patients with refractory diffuse large B cell lymphoma.

Authors:  Yu Cai; Liping Wan; Juan Yang; Jun Zhu; Jieling Jiang; Su Li; Xianmin Song; Chun Wang
Journal:  Ann Hematol       Date:  2019-02-04       Impact factor: 3.673

3.  Comparison of Three Distinct Prophylactic Agents Against Invasive Fungal Infections in Patients Undergoing Haplo-identical Hematopoietic Stem Cell Transplantation and Post-transplant Cyclophosphamide.

Authors:  Jean El-Cheikh; Roberto Crocchiolo; Andrea Vai; Sabine Furst; Stefania Bramanti; Barbara Sarina; Angela Granata; Catherine Faucher; Bilal Mohty; Samia Harbi; Reda Bouabdallah; Norbert Vey; Armando Santoro; Christian Chabannon; Luca Castagna; Didier Blaise
Journal:  Mediterr J Hematol Infect Dis       Date:  2015-08-20       Impact factor: 2.576
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.